Comparison of cumulative live birth rates between progestin-primed ovarian stimulation protocol and gonadotropin-releasing hormone antagonist protocol in different populations

Comparison of cumulative live birth rates between progestin-primed ovarian stimulation protocol and gonadotropin-releasing hormone antagonist protocol in different populations

ObjectiveTo compare cumulative live birth rate (LBR) between progestin-primed ovarian stimulation (PPOS) and GnRH antagonist protocols of preimplantation genetic testing (PGT) cycles in different populations.MethodsThis was a retrospective cohort study. A total of 865 patients were enrolled and sepa...

Full description

Bibliographic Details
Main Authors:	Ruiqiong Zhou, Mei Dong, Li Huang, Songlu Wang, Lin Fan, Xiangping Liang, Xiqian Zhang, Fenghua Liu
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2023-04-01
Series:	Frontiers in Endocrinology
Subjects:	progestin-primed ovarian stimulation GnRH antagonist cumulative live birth rate preimplantation genetic testing normal ovarian responder PCOS
Online Access:	https://www.frontiersin.org/articles/10.3389/fendo.2023.1117513/full

Similar Items

Progestin-Primed Ovarian Stimulation versus GnRH Antagonist Protocol for Ovarian Stimulation in IVF: A Prospective Pilot Study
by: Tien K. Le, et al.
Published: (2024-03-01)

Non-inferiority of progestin-primed ovarian stimulation versus GnRH antagonist protocol: A propensity score-weighted analysis
by: Le Duc Thang, et al.
Published: (2024-04-01)

Progestin Primed Ovarian Stimulation (PPOS) protocol yields lower euploidy rate in older patients undergoing IVF
by: Angel Hsin-Yu Pai, et al.
Published: (2023-08-01)

Ovarian sensitivity index affects clinical pregnancy and live birth rates in gonadotropin-releasing hormone agonist and antagonist in vitro fertilization cycles
by: Chao Chin Hsu, et al.
Published: (2024-12-01)

Comparison of the neonatal outcomes of progestin-primed ovarian stimulation and flexible GnRH antagonist protocols: a propensity score–matched cohort study
by: Mingze Du, et al.
Published: (2023-06-01)

Micronized natural progesterone (Seidigestan®) vs GnRH antagonists for preventing the LH surge during controlled ovarian stimulation (PRO_NAT study): study protocol of a randomized clinical trial
by: M. Martínez-Moya, et al.
Published: (2024-03-01)

Association between serum LH levels on hCG trigger day and live birth rate after fresh embryo transfer with GnRH antagonist regimen in different populations
by: Ruiqiong Zhou, et al.
Published: (2023-07-01)

A prediction model for high ovarian response in the GnRH antagonist protocol
by: Yilin Jiang, et al.
Published: (2023-11-01)

Clinical development of the oral gonadotropin-releasing hormone antagonist elagolix
by: Kristof Chwalisz, M.D., Ph.D.
Published: (2023-06-01)

Ovarian response determines the luteinizing hormone suppression threshold for patients following the gonadotrophin releasing hormone antagonist protocol: A retrospective cohort study
by: Qingfang Li, et al.
Published: (2024-01-01)

Overactivation of GnRH neurons is sufficient to trigger polycystic ovary syndrome-like traits in female miceResearch in context
by: Mauro S.B. Silva, et al.
Published: (2023-11-01)

Comparison of hCG Versus Gonadotropin-Releasing Hormone Agonist to Induce Oocyte Maturation in Assisted Reproductive Technology Cycles: A Retrospective Cohort Study
by: Gulay Beydilli Nacak, et al.
Published: (2021-08-01)

Effects of gonadotropin-releasing hormone antagonist (GnRH-ant) cessation on trigger day in a GnRH-ant protocol: a meta-analysis
by: Xueying Li, et al.
Published: (2025-12-01)

Comparison of Controlled Ovarian Stimulation Protocols on IVF Outcome in Normal and Poor Responders
by: Deniz Esinler, et al.
Published: (2013-12-01)

Evaluation of the Impact of Letrozole in Combination with the GnRH Antagonist Ovarian Stimulation Protocol in Patients Expected to Have a Poor Ovarian Response (POSEIDON Groups 3 and 4)
by: Bulut Varlı, et al.
Published: (2024-02-01)

GnRH pulse generator activity in mouse models of polycystic ovary syndrome
by: Ziyue Zhou, et al.
Published: (2025-01-01)

Progesterone change in the late follicular phase affects pregnancy rates both agonist and antagonist protocols in normoresponders: a case-controlled study in ICSI cycles
by: Berfu Demir, et al.
Published: (2016-05-01)

Meta-analysis of trigger timing in normal responders undergoing GnRH antagonist ovarian hyperstimulation protocol
by: Qijun Xie, et al.
Published: (2024-03-01)

Role of Gonadotropin-Releasing Hormone (GnRH) in Ovarian Cancer
by: Carsten Gründker, et al.
Published: (2021-02-01)

Coasting Versus GnRH Antagonist Salvage for the Prevention of Ovarian Hyperstimulation Syndrome
by: Cavidan Gülerman, et al.
Published: (2013-12-01)

Editorial: Benefits and risks of agonist triggering strategies
by: Jan Tesarik
Published: (2024-12-01)

Spontaneous and iatrogenic ovarian hyperstimulation syndrome in the absence of FSHR mutations: a case report of two unexpected cases
by: Jessica Daolio, et al.
Published: (2023-03-01)

Rapid reduction of adenomyosis coexisting with leiomyoma volume during treatment with Relugolix
by: Keitaro Yamanaka, et al.
Published: (2023-12-01)

LH level on trigger day, number of follicles ≥16 mm but <18 mm, and number of retrieved oocytes are independent risk factors for polyspermy in gonadotropin-releasing hormone antagonist protocol
by: Qiongyu Wu, et al.
Published: (2024-12-01)

Effect of LH level on HCG trigger day on clinical outcomes in patients with diminished ovarian reserve undergoing GnRH-antagonist protocol
by: Qianjie Zhang, et al.
Published: (2024-08-01)

Effects of different gonadotropin preparations in GnRH antagonist protocol for patients with polycystic ovary syndrome during IVF/ICSI: a retrospective cohort study
by: Zhengyan Hu, et al.
Published: (2024-02-01)

Adverse cardiovascular effect following gonadotropin-releasing hormone antagonist versus GnRH agonist for prostate cancer treatment: A systematic review and meta-analysis
by: Li Gu, et al.
Published: (2023-03-01)

Clinical applications of gonadotropin-releasing hormone analogues: a broad impact on reproductive medicine
by: Farrah L. Saleh, M.D., et al.
Published: (2023-06-01)

Co-administration of GnRH-agonist and hCG (double trigger) for final oocyte maturation increases the number of top-quality embryos in patients undergoing IVF/ICSI cycles
by: Binbin Tu, et al.
Published: (2024-07-01)

Phase 2, double-blind, randomized, placebo-controlled study of the safety and efficacy of elagolix in women with polycystic ovary syndrome
by: Michael C. Snabes, M.D., Ph.D., et al.
Published: (2023-06-01)

Luteal Support with very Low Daily Dose of Human Chorionic Gonadotropin after Fresh Embryo Transfer as an Alternative to Cycle Segmentation for High Responders Patients Undergoing Gonadotropin-Releasing Hormone Agonist-Triggered IVF
by: Andrea Roberto Carosso, et al.
Published: (2021-03-01)

Validating the Use of Corifollitropin Alfa in Progestin-Primed Ovarian Stimulation Protocol on Normal and High Responders by Comparing with Conventional Antagonist Protocol: A Retrospective Study
by: Chen-Yu Huang, et al.
Published: (2020-06-01)

Editorial: GnRH agonist triggering of final oocyte maturation: Improving safety without compromising success
by: Johnny Awwad, et al.
Published: (2023-03-01)

Pretreatment with or without GnRH-agonist before frozen–thawed embryo transfer in patients with PCOS: a systematic review and meta-analysis
by: Jie Li, et al.
Published: (2024-06-01)

Prevention of Ovarian Hyper stimulation Syndrome by using gonadotrophic releasing hormone analogue to induce final ovulation trigger in invitro fertilization cycles
by: Safia Sultana, et al.
Published: (2023-04-01)

Oral dydrogesterone along with vaginal micronized progesterone supplementation for luteal phase support in IVF patients, and its impact on pregnancy and live birth rates: a prospective randomized trial
by: Leonardo Rinaldi, et al.
Published: (2024-12-01)

Introduce an optimal method of ovarian stimulation in the polycystic ovarian syndrome affected: a randomized controlled trial
by: Azar Yahyaei, et al.
Published: (2023-06-01)

Hypothalamic neuroglial plasticity is regulated by anti-Müllerian hormone and disrupted in polycystic ovary syndromeResearch in context
by: Anne-Laure Barbotin, et al.
Published: (2023-04-01)

Effectiveness and safety of GnRH antagonist originator and generic in real-world clinical practice: a retrospective cohort study
by: Mingzhu Cao, et al.
Published: (2024-06-01)

The role of elagolix in ovulation suppression during controlled ovarian stimulation: a retrospective cohort study
by: David Soliman, M.Sc., et al.
Published: (2024-12-01)